// Force accordion to work document.addEventListener('DOMContentLoaded', function() { var triggers = document.querySelectorAll('.benefit-trigger'); for (var i = 0; i < triggers.length; i++) { triggers[i].addEventListener('click', function(e) { var item = this.closest('.benefit-item'); var body = item.querySelector('.benefit-body'); var isOpen = item.classList.contains('open'); // Close all others var allItems = document.querySelectorAll('.benefit-item'); for (var j = 0; j < allItems.length; j++) { if (allItems[j] !== item) { allItems[j].classList.remove('open'); allItems[j].querySelector('.benefit-body').style.maxHeight = '0'; } } // Toggle this one if (!isOpen) { item.classList.add('open'); body.style.maxHeight = body.scrollHeight + 'px'; } else { item.classList.remove('open'); body.style.maxHeight = '0'; } }); } });

Clinical Update Series · Issue 1

Clinical Intelligence on Helicobacter pylori

"Updated Guidelines for H. pylori Eradication: Optimizing Treatment in the Era of Rising Antibiotic Resistance"

44%

Global Prevalence

#1

Group I Carcinogen

15%

Resistance Threshold

5

Key Guideline Updates

Explore

💡 Did You Know?

4.4B

People worldwide carry H. pylori — more than half the global population lives with this chronic infection.

6×

H. pylori-infected individuals have up to 6× higher risk of developing gastric cancer compared to uninfected individuals.⁴

15%

When clarithromycin resistance exceeds this threshold, traditional triple therapy should no longer be used as first-line treatment.²

Abstract

The Global H. pylori Challenge

Helicobacter pylori infection remains one of the most common chronic bacterial infections globally, strongly associated with peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma.¹

Recent international guidelines emphasize that appropriate eradication therapy is essential to reduce disease burden and prevent gastric cancer.² However, increasing resistance to commonly used antibiotics such as clarithromycin and levofloxacin has significantly reduced the effectiveness of traditional triple therapy regimens.³

Contemporary recommendations therefore support resistance-guided therapy, preference for bismuth-based quadruple regimens in many regions, and confirmation of eradication following treatment.^2,4

Key Highlights

Globally prevalent: Affects nearly half the world's population

Group I Carcinogen: IARC classification reflects direct gastric cancer link

Resistance crisis: Clarithromycin & levofloxacin resistance rising globally

New standard: Bismuth quadruple therapy now preferred first-line

Mandatory testing: Eradication confirmation required post-treatment

Clinical Benefits

Why Eradication Matters

Tap each benefit to explore the clinical evidence. Successful eradication offers multidimensional protection across the GI spectrum.

🩹

Healing of Active Gastric & Duodenal Ulcers

▼

Eradication of H. pylori accelerates ulcer healing and dramatically reduces the need for long-term acid suppression therapy. Multiple randomized controlled trials confirm that eradication leads to superior healing outcomes compared to acid suppression alone.⁵

🔁

Prevention of Ulcer Recurrence & GI Bleeding

▼

Without eradication, ulcer recurrence rates approach 80% within one year. Successful eradication reduces this to under 10%, and dramatically cuts the risk of life-threatening ulcer-related gastrointestinal bleeding, particularly in patients on NSAIDs or anticoagulants.⁶

🎗

Reduction in Long-Term Gastric Cancer Risk

▼

H. pylori eradication is associated with a significant reduction in gastric cancer incidence — by up to 35–40% in high-risk populations. As a Group I IARC carcinogen, treating H. pylori is now considered a genuine cancer prevention strategy.^4,10

😌

Symptom Improvement in Functional Dyspepsia

▼

In H. pylori-positive patients with functional dyspepsia, eradication therapy provides meaningful and durable symptom relief. Meta-analyses show a number needed to treat (NNT) of approximately 14 — a clinically meaningful benefit.⁷

🧫

Regression of Early-Stage Gastric MALT Lymphoma

▼

Perhaps most remarkably, eradication of H. pylori alone leads to complete regression in approximately 75% of early-stage, localized gastric MALT lymphoma cases — effectively curing a cancer without chemotherapy or radiation.⁸

Guideline Updates

5 Practice-Changing Updates

Navigate each updated recommendation from the Maastricht VI/Florence Consensus Report and ACG 2024 guidelines.

01 · Resistance 02 · First-Line Therapy 03 · Individualization 04 · Confirmation 05 · Cancer Prevention

01

Rising Global Antibiotic Resistance

Antibiotic resistance is now one of the primary drivers of eradication failure. Resistance to clarithromycin and levofloxacin has increased substantially across multiple regions worldwide.³

Empirical clarithromycin-based triple therapy is no longer recommended in regions where resistance exceeds 15%. Clinicians must check local susceptibility data before prescribing.²

Clarithromycin Resistance Threshold

15% — Critical Limit

Levofloxacin Resistance (many regions)

>20% — High Risk

⚠ Always consult local/regional resistance data before selecting therapy

02

Bismuth Quadruple: The New Standard

Recent international guidelines recommend bismuth-based quadruple therapy as the preferred first-line treatment in many settings due to its consistently higher eradication rates despite growing antibiotic resistance.²

Clinical studies demonstrate superior efficacy over traditional triple therapy, making it the go-to choice in high-resistance regions.⁹

Recommended Regimen

💊

Proton Pump Inhibitor (PPI)

⚗️

Bismuth Salt

🧬

Tetracycline

💉

Metronidazole

03

Individualized Treatment Strategy

Modern guidelines emphasize personalized therapy selection. A one-size-fits-all approach is no longer adequate in the era of rising resistance.²

Selection should be based on: previous antibiotic exposure, regional resistance patterns, patient adherence and tolerance, and availability of susceptibility testing. This approach curbs further resistance development while improving success rates.

Factors to Consider

📋

Previous antibiotic exposure

🌍

Regional resistance patterns

🤝

Patient adherence & tolerance

🔬

Susceptibility testing availability

04

Confirmation of Eradication: Mandatory

Successful eradication must always be confirmed after completing therapy.² Post-treatment testing is no longer optional — it is a clinical standard of care.

Testing should be performed at least 4 weeks after therapy completion, and 1–2 weeks after PPI discontinuation to ensure accurate results.²

Confirmation Tests

RecommendedUrea Breath Test

Highly accurate, non-invasive. Sensitivity >95%. Perform ≥4 weeks post-therapy, 1–2 weeks off PPIs.

AlternativeStool Antigen Test

Reliable non-invasive alternative. Same timing requirements. Avoid antibiotics ≥4 weeks prior.

05

Gastric Cancer Prevention

Eradication of H. pylori has been shown to reduce gastric cancer incidence, especially in high-risk populations — by up to 35–40% in some studies.¹⁰

Population-based screening and eradication strategies are increasingly being explored worldwide, positioning H. pylori treatment as a public health cancer prevention intervention, not just a GI therapy.¹⁰

Cancer Risk Reduction with Eradication

Up to 39% Reduction¹⁰

"H. pylori eradication is the most cost-effective strategy for primary prevention of gastric cancer currently available."

Quick Facts — Hover or Tap to Reveal

Test Your Knowledge

Flip each card to discover the clinical insight behind each key concept.

01

What makes H. pylori uniquely dangerous?

↩ Tap to reveal

It's one of the only bacteria classified as a Group I carcinogen — in the same risk category as tobacco — because of its direct causal link to gastric cancer.⁴

02

Why is triple therapy no longer first-line?

↩ Tap to reveal

Rising clarithromycin resistance globally has dramatically reduced triple therapy success rates below acceptable levels in many regions.³

03

Can eradication actually cure a cancer?

↩ Tap to reveal

Yes — approximately 75% of early-stage gastric MALT lymphomas regress completely with H. pylori eradication alone, without chemotherapy.⁸

04

When should you confirm eradication?

↩ Tap to reveal

At least 4 weeks after completing therapy, and 1–2 weeks after stopping PPIs — earlier testing risks false-negative results.²

Clinical Practice Takeaways

Your Action Checklist

Evidence-based steps every clinician should apply in H. pylori management today.

✔

Treat all confirmed H. pylori infections whenever clinically feasible²

✔

Check regional antibiotic resistance data before selecting any therapy³

✔

Prefer bismuth-based quadruple therapy regimens in high-resistance settings²

✔

Always confirm eradication — minimum 4 weeks after therapy completion²

✔

Consider H. pylori eradication as an active gastric cancer prevention strategy¹⁰

References

Evidence Base

1

Hooi JKY et al. Global prevalence of H. pylori infection: systematic review and meta-analysis. Gastroenterology. 2017.

2

Malfertheiner P et al. Management of H. pylori infection: Maastricht VI/Florence Consensus Report. Gut. 2022.

3

Savoldi A et al. Prevalence of antibiotic resistance in H. pylori. Gastroenterology. 2018.

4

IARC. Helicobacter pylori as a carcinogen. IARC Monographs. 2012.

5

Chey WD et al. ACG Clinical Guideline: Treatment of H. pylori Infection. Am J Gastroenterol. 2024.

6

Ford AC et al. Eradication therapy for peptic ulcer disease. Cochrane Database Syst Rev. 2016.

7

Moayyedi P et al. H. pylori eradication for functional dyspepsia. BMJ. 2019.

8

Zullo A et al. Regression of gastric MALT lymphoma after H. pylori eradication. Ann Intern Med. 2010.

9

Li BZ et al. Bismuth quadruple therapy for H. pylori eradication. Aliment Pharmacol Ther. 2015.

10

Lee YC et al. Association between H. pylori eradication and gastric cancer prevention. Gastroenterology. 2016.

/* Force accordion to work */ .benefit-item .benefit-body { max-height: 0 !important; overflow: hidden !important; transition: max-height 0.4s ease !important; } .benefit-item.open .benefit-body { max-height: 500px !important; overflow: visible !important; } .benefit-trigger { cursor: pointer !important; }